Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral...

Related Keywords

United Kingdom ,United States ,British ,Rosalia Scampoli ,Katie Mcmanus ,Trevi Haduvio ,Linkedin ,Prnewswire Trevi Therapeutics Inc ,Company On Twitter ,Drug Administration ,Nasdaq ,Exchange Commission ,British Thoracic Society Winter Meeting ,Trevi Therapeutics Inc ,Jennifer Good ,Chronic Cough ,Idiopathic Pulmonary ,Trevi Therapeutics ,Private Securities Litigation Reform Act ,Operations Data ,Nc ,